BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11355325)

  • 1. Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
    Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Fan FS; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
    Int J Colorectal Dis; 2001 Apr; 16(2):96-101. PubMed ID: 11355325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer.
    Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(44):388-92. PubMed ID: 11995458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA).
    Hanke B; Riedel C; Lampert S; Happich K; Martus P; Parsch H; Himmler B; Hohenberger W; Hahn EG; Wein A
    Ann Oncol; 2001 Feb; 12(2):221-6. PubMed ID: 11300328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer.
    Scholnik AP; Arnold DJ; Walker WS; Schwenke P; Suhrland LG; Balcueva EP; Dimitrov NV
    Am J Clin Oncol; 1988 Oct; 11(5):558-63. PubMed ID: 3263037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer.
    Tsai HL; Chang YT; Chu KS; Chen CF; Yeh YS; Ma CJ; Wu DC; Kuo CH; Chan HM; Sheen MC; Wang JY
    Int J Biol Markers; 2008; 23(4):244-8. PubMed ID: 19199273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High and low dose folinic acid, 5-fluorouracil bolus and continuous infusion for poor-prognosis patients with advanced colorectal carcinoma.
    Bano N; Najam R; Mateen A; Qazi F
    Asian Pac J Cancer Prev; 2012; 13(8):3589-93. PubMed ID: 23098438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
    Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.
    De Gramont A; Krulik M; Cady J; Lagadec B; Maisani JE; Loiseau JP; Grange JD; Gonzalez-Canali G; Demuynck B; Louvet C
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1499-503. PubMed ID: 3263275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predictive of response and survival in patients with metastatic colorectal cancer in Taiwan.
    Wang WS; Fan FS; Hsieh RK; Chiou TJ; Lin JK; Lin TC; Yen CC; Liu JH; Hsu H; Chen PM
    Jpn J Clin Oncol; 1997 Jun; 27(3):174-9. PubMed ID: 9255273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
    Streit M; Jaehde U; Stremetzne S; Ridwelski K; Kerz H; Strohbach F; Hohenberger P; Zwiebel FM; Hebart H; Böthig R; Kairies M; Zillig D; Schuchmann S; Warnecke S; Thiel E; Kreuser ED
    Ann Oncol; 1997 Nov; 8(11):163-5. PubMed ID: 9426339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
    Behr TM; Salib AL; Liersch T; Béhé M; Angerstein C; Blumenthal RD; Fayyazi A; Sharkey RM; Ringe B; Becker H; Wörmann B; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3232s-3242s. PubMed ID: 10541369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
    Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
    Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
    J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer.
    Leichman CG; Leichman L; Spears CP; Rosen PJ; Jeffers S; Groshen S
    J Natl Cancer Inst; 1993 Jan; 85(1):41-4. PubMed ID: 8416255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer.
    Goldstein MJ; Mitchell EP
    Cancer Invest; 2005; 23(4):338-51. PubMed ID: 16100946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
    Kim G; Jung EJ; Ryu CG; Hwang DY
    Yonsei Med J; 2013 Jan; 54(1):116-22. PubMed ID: 23225807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.
    Hartmann JT; Köhne CH; Schmoll HJ; Daikeler T; Kanz L; Bokemeyer C
    Oncology; 1998; 55(4):320-5. PubMed ID: 9663421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.